Circulating procalcitonin in aseptic carcinoma patients: A specificity study with 18F-fluorodeoxyglucose positron-emission tomography/computed tomography as benchmark

Clinical Chemistry and Laboratory Medicine

Volumn 48, Issue 8, 2010, Pages 1163-1165

  Giovanella, Luca ^a,b   Suriano, Sergio ^a   Ricci, Riccardo ^a   Ravani, Paolo ^b   Ceriani, Luca ^a  

^a ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^b REGIONAL HOSPITAL OF LUGANO   (Switzerland)

Author keywords

18F fluorodeoxyglucose; carcinoma; positron emission tomography; procalcitonin

Indexed keywords

C REACTIVE PROTEIN; FLUORODEOXYGLUCOSE F 18; PROCALCITONIN;

ADULT; ARTICLE; BREAST CARCINOMA; CANCER PATIENT; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE SEVERITY; FEMALE; HEAD AND NECK CARCINOMA; HORMONE BLOOD LEVEL; HUMAN; INFECTION; INFLAMMATION; KIDNEY FAILURE; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEUROENDOCRINE TUMOR; OVARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROCALCITONIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SEPSIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; THYROID MEDULLARY CARCINOMA; UTERINE CERVIX CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CALCITONIN; CARCINOMA; COHORT STUDIES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; PROTEIN PRECURSORS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77955438441     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2010.214     Document Type: Article

References (26)

1. Williams MD, Braun LA, Cooper LM, Johnston J, Weiss RV, Qualy LQ, et. al. Hospitalized cancer patients with severe sepsis: analysis of incidence, mortality and associated costs of care. Crit Care 2004;8:291-298
2. Chanock S. Evolving risk factors for infectious complications of cancer therapy. Hematol Oncol Clin North Am 1993;7:771-793
3. Buchheidt D, Hummel M, Engelich G, Hehlmann R. Management of infections in critically ill neutropenic cancer patients. J Crit Care 2004;3:165-173
4. Le Moullec JM, Jullienne A, Chenais J, Lasmoles F, Guliana JM, Milhaud G, et. al. The complete sequence of human preprocalcitonin. FEBS 1984;167:93-97
5. Müller B, White JC, Nylen ES, Snider RH, Becker KL, Habener JF. Ubiquitous expression of the calcitonin-Igene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 2001;86: 396-404.
6. Müller B, Becker KL, Schachinger H, Rickenbacher PR, Huber PR, Zimmerli W, et. al. Calcitonin precursors are reliable markers of sepsis in a medical intensive care unit. Crit Care Med 2000;28: 977-983
7. Mofidi R, Suttie S, Patil P, Ogston S, Parks R. The value of procalcitonin at predicting the severity of acute pancreatitis and development of infected pancreatic necrosis: systematic review. Surgery 2009;146:72-81.
8. Schneider HG, Lam QT. Procalcitonin for the clinical laboratory: a review. Pathology 2007;39:383-390
9. Gendrel D, Reymond J, Coste J, Moulin F, Lorrot M, Guerin S, et. al. Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections. Pediatr Infec Dis J 1999;18:871-881
10. Harbarth S, Holeckova K, Froidevaux C, Pittet D, Ricou B, Grau GE, et. al. Diagnostic value of procalcitonin, interleukin- 6, and interleukin-8 in critically ill patients admitted with suspected sepsis. Am J Respir Crit Care Med 2001;164:396-402.
11. Ito S, Sato N, Kojika M, Ygashi Y, Suzuki Y, Suzuki K, et. al. Serum procalcitonin levels are elevated in esophageal cancer patients with postoperative infectious complications. Eur Surg Res 2005;37:22-28
12. Montagnana M, Minicozzi AM, Salvagno GL, Danese E, Cordiano C, De Manzoni G, et. al. Postoperative variation of C-reactive protein and procalcitonin in patients with gastrointestinal cancer. Clin Lab 2009;55:187-192
13. Kallio R, Surcel HM, Bloigu A, Syrjala H. C-reactive protein, procalcitonin and interleukin-8 in the primary diagnosis of infections in cancer patients. Eur J Cancer 2000;36:889-894
14. Bayer L, Schoentube M, Dorrfel W. C-reactive protein, Il-6 and procalcitonin as infection parameters in children with oncologic diseases. Klin Paediatr 2000;21:326-331
15. Matzaraki V, Alexandraki KI, Venetsanou K, Piperi C, Myrianthefs P, Malamos N, et. al. Evaluation of serum procalcitonin and interleukin-6 levels as markers of liver metastasis. Clin Biochem 2007;40:336-342
16. Bomanji JB, Costa DC, Ell PJ. Clinical role of positron emission tomography in oncology. Lancet Oncol 2001;2:157-164
17. Jadvar H, Alavi A, Gambhir SS. 18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med 2009;50:1820-1827
18. Kumar A, Kumar R, Seenu V, Gupta SD, Chawla M, Malhotra A, et. al. The role of 18F-FDG PET/CT in evaluation of early response to neoadjuvant chemotherapy in patients with locally advanced br east cancer. Eur Radiol 2009;19:1347-1357
19. Fletcher JW, Djulbegovic B, Soares HP, Siegel BA, Lowe VJ, Lyman GH, et. al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med 2008;49:480-508.
20. Oyen WJ, Mansi L. FDG-PET in infectious and inflammatory disease. Eur J Nucl Med Mol Imaging 2003;30:1568-1570
21. Love CL, Tomas MB, Tronco GG, Palestro CJ. FDG PET of infection and inflammation. Radiographics 2005;25:1357-1368
22. Buysschaert I, Vanderschueren V, Blockmans D, Mortelmans L, Knockaert D. Contribution of 18fluoro-deoxyglucose positron emission tomography to the work-up of patients with fever of unknown origin. Eur J Int Med 2004;15:151-156
23. Bleeker-Rovers CP, Vos FJ, Mudde AH, Dofferhoff AS. A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin. Eur J Nucl Med Mol Imaging 2007;34:694-703.
24. Algeciras-Schimnich A, Preissenr CM, Theobald P, Finseth MS, Grebe SG. Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 2009;94:861-868
25. Ghillani PP, Mottè P, Troalen F, Jullienne A, Gardet P, Le Chevalier T, et. al. Identification and measurement of calcitonin precursors in serum of patients with malignant diseases. Cancer Res 1989;49:6845-6851
26. Struck J, Strebelow M, Tietz S, Alonso C, Morghentaler NG, van der Hoeven JG, et. al. Method for the selective measurement of amino-terminal variants of procalcitonin. Clin Chem 2009; 55:1672-1679